Figwort

Figwort (Scrophularia spp.): A Comprehensive Reference

1. Identity and Botanical Classification

Taxonomy and Species

"Figwort" is the common name for the genus Scrophularia, which belongs to the family Scrophulariaceae and includes approximately 350 species. Many species grow wild in nature and have not been cultivated, while some are considered endangered. Among the dozens of species with documented medicinal use, three are of primary pharmacological and commercial interest:

• Scrophularia nodosa L. — Common figwort or knotted figwort; the principal species in European herbal medicine.
• Scrophularia ningpoensis Hemsl. — Known as Xuanshen (玄参) in Traditional Chinese Medicine; the primary figwort species in East Asian medicine.
• Scrophularia striata Boiss. — A species native to Iran, with notable contemporary clinical research into wound healing.

Nomenclature and Etymology

The genus name Scrophularia derives from the Latin term scrofula, referring to a tubercular disease affecting the lymph nodes historically known as the "King's Evil." This etymology stems from the doctrine of signatures, an ancient herbal tradition associating the plant's knobby structures with its supposed efficacy in treating skin conditions and swellings resembling scrofula. The species epithet nodosa originates from the Latin nodus, meaning "knot" or "node," alluding to the plant's distinctive knotted and tuberous rootstock, which features prominent nodules.

The common name "figwort" itself also arises from the doctrine of signatures, linking the plant's nodular roots to the treatment of hemorrhoids, which were colloquially called "figs" in Old English. The term "wort" is an archaic English word for "plant" or "herb," often denoting medicinal use.

Other common names for S. nodosa include knotted figwort, woodland figwort, rosenoble, throatwort, carpenter's square, kernelwort, and scrophula plant. In Spanish it is known as escrophularia, in Danish as knoldbrunro, in German as Knotige Braunwurz, and in French as scrophulaire noueuse.

Botanical Description and Habitat

Scrophularia nodosa is a perennial herbaceous plant characterized by erect, square stems reaching 30–150 cm in height, opposite lanceolate to ovate leaves with toothed margins up to 120 mm long, and bilaterally symmetrical flowers that are greenish-brown to pinkish-red, forming dense terminal clusters. S. nodosa is native to Europe, including Britain, and extends south and east from Norway to Spain and into temperate Asia. It grows on damp ground in woods, hedgebanks, and by streams.

The species is Eurosiberian temperate in its phytogeography, widespread in Europe and western Asia, but noticeably thinning towards both north and south in Scandinavia and the Mediterranean. It is rarely recorded in eastern North America, where it is an introduction, and it has also been introduced to South Island, New Zealand.

Parts Used and Commercial Forms

Figwort is an herb, and the whole plant is used to make medicine. In practice, the aerial parts (flowering tops and leaves) of S. nodosa are most commonly harvested in Western herbal traditions, while the dried root (Radix Scrophulariae, or Scrophulariae Radix) is the primary medicinal part in East Asian medicine. Common commercial forms include:

• Dried herb (bulk or in capsule form)
• Alcoholic tinctures
• Aqueous infusions (teas/decoctions)
• Topical preparations: compresses, poultices, ointments, and hydroalcoholic extracts

2. Traditional and Historical Use

European Traditions

S. nodosa has a long history in traditional herbal medicine, particularly in Europe, where it was employed for its diuretic, anodyne, and anti-inflammatory properties. It was traditionally used to treat various skin conditions, including eczema, psoriasis, pruritus, and scrofula (a form of tuberculosis affecting the lymph nodes), as well as wounds, swellings, hemorrhoids, and rheumatism.

In the Middle Ages, the herb was thought to be one of the best medicinal plants to treat swellings and tumors. The genus name Scrophularia comes from the plant's traditional use as a remedy for scrofula, a tuberculous infection of the lymph nodes in the neck — a connection based on the resemblance of the bulbous shape of the plant's rhizomes to swollen glands, explained by the doctrine of signatures, a philosophy shared by herbalists from the time of Galen (130–200 AD).

S. nodosa was called "the Scrofula Plant" on account of its value in treating all forms of cutaneous eruptions, abscesses and wounds, and was formerly considered a specific for this purpose. The earliest well-documented mention of Scrophularia nodosa appears in John Parkinson's 17th-century herbal, Theatrum Botanicum, where he noted its affinity for treating swellings and skin inflammations.

Nicholas Culpeper, a 17th-century English herbalist and physician, named the herb "throatwort," as figwort was used for treating scrofular conditions of the throat. In European folk medicine, figwort was carried in pouches to "ward off contagion," and a decoction was applied topically to soothe sores and ulcers.

In Europe, species such as S. aquatica L. (water figwort) were used as laxatives, heart stimulants, circulatory stimulants, and diuretics.

Traditional European uses included treatment of skin conditions such as eczema, psoriasis, and pruritus, as well as wounds, swellings, hemorrhoids, and rheumatism. Preparations typically involved decoctions or tinctures made from the whole plant or roots, administered internally to act as a mild purgative, alterative for blood purification, and anthelmintic for expelling intestinal worms.

The common figwort, S. nodosa, has also been employed in Ireland historically for the treatment of wounds.

North American Indigenous and Colonial Use

Scrophularia species endemic to North America — including S. lanceolata and S. marilandica — were historically used by indigenous peoples and colonialists to treat sunburn, sunstroke, frostbite, and edema, as well as for blood purification and in women's health.

Traditional Chinese Medicine

Scrophularia ningpoensis Hemsl is a commonly used medicinal plant in East Asia. The dried roots, known as Scrophulariae Radix (SR), are one of the most commonly used medicinal parts and have been widely used in East Asia for more than 2,000 years. In TCM, SR is used for clearing away heat and cooling blood, nourishing Yin and reducing fire, and detoxicating and resolving masses.

Known in TCM as Xuan Shen (玄参), this herb is classified as salty, sweet, bitter, and cold, and enters the Kidney, Lung, and Stomach meridians. Traditionally, it clears heat and cools the blood and is a major herb for severe heat with sore throat, fever, toxicity, or blood-level heat that dries fluids, most often applied for sore throat, scrofula, and thyroid nodule.

Roots of S. ningpoensis ("Xuan Shen") and S. nodosa (common figwort) have been used as therapeutic remedies in fever, swelling, constipation, pharyngitis, neuritis, and laryngitis.

In Chinese traditional medicine, the dried root of S. buergeriana Miquel is used for the treatment of neuritis, fever, and pharyngitis.

Traditional Iranian Medicine

In ancient Iranian medicine, roots and aerial parts of S. lucida L. ("Sinderitis") and related species have been used as heart and circulatory stimulants. Many Scrophularia plants have been used in Asian countries as a medicinal herb for the treatment of various diseases such as allergy, cancer, rheumatism, cardiovascular, and chronic inflammatory disorders.

Scrophularia striata, found in Kurdistan and Ilam regions of Iran and locally known as "Teshnedari," has been traditionally used for its wound healing and anti-inflammatory properties, especially for the treatment of ear infections.

3. Key Constituents and Active Compounds

Primary Phytochemical Classes

Comprehensive phytochemical analysis of the genus has identified 204 compounds in total; glycoside esters, iridoid glycosides, and triterpenoids are the most common compound classes across the genus. More than 162 compounds have been identified and isolated from S. ningpoensis alone, including iridoids and iridoid glycosides, phenylpropanoid glycosides, organic acids, volatile oils, terpenoids, saccharides, flavonoids, sterols, and saponins.

Scrophularia nodosa contains saponins, cardioactive glycosides, flavonoids, resin, sugar, and organic acids. Common figwort more specifically contains amino acids, flavonoids, phenolic acids (ferulic acid, vanillic acid, caffeic acid, cinnamic acid), saponins, cardiac glycoside, phytosterols, essential fatty acids, and asparagine.

Iridoid Glycosides

Iridoid glycosides constitute the most pharmacologically significant compound class in figwort. Key iridoids identified in S. nodosa include aucubin, harpagosides, harpagide, and catalpol. Harpagoside, one of the central iridoids, is thought — together with one or more iridoid and phenylethanoid/phenylpropanoid glycosides — to be responsible for the anti-inflammatory properties of the various extracts, salves, and tinctures made from these plants. Whether harpagoside alone may not be sufficient for anti-inflammatory activity toward many conditions, it is a useful molecular marker; leaves of North American Scrophularia species produce up to 1.2% harpagoside, which is similar to amounts reported in the leaves of Scrophularia nodosa.

Iridoid and phenylpropanoid glycosides are thought to be the major components of Radix Scrophulariae responsible for its beneficial activities and may also act synergistically.

Scrophularia striata is particularly rich in iridoid glycosides, notably aucubin and catalpol, known for their anti-tumour, anti-inflammatory, and antimicrobial properties.

Phenylethanoid and Phenylpropanoid Glycosides

One of the main constituents of Scrophularia plants is phenylethanoid glycosides, and many of the therapeutic potentials can be attributed to them. Key compounds in this class include acetoside (verbascoside/acteoside), angoroside C, and cinnamic acid derivatives. Verbascoside (synonyms: acteoside and kusaginin) and harpagide are recognized anti-inflammatory metabolites within this class that have been detected in multiple Scrophularia species.

Flavonoids

Seven known compounds of flavonoid nature have been isolated from the chloroform fraction of crude extract of S. nodosa. Flavonoids identified in S. nodosa include diosmin. The flavonoid hispidulin has also been identified in related species. Phenolic acids identified in S. nodosa include caffeic acid, ferulic acid, and vanillic acid.

Cardioactive Glycosides

Scrophularia nodosa contains cardioactive glycosides, and has traditionally been noted to possess cardiac stimulant properties. Among the plant's constituents, agents with antioxidant activity (aromatic and phenolic compounds) play a primary role in prevention and treatment of ischemic heart injuries, particularly arrhythmias; and the presence of compounds like glycosides can improve cardiac contractility in both ischemic and reperfused conditions.

Mechanism of Action of Key Constituents

Harpagoside decreases IκB-α protein phosphorylation and inhibits p65 protein translocation from the cytosol to the nucleus, thereby suppressing NF-κB activation and reducing HIF-1α generation — demonstrating that the anti-inflammatory mechanism of harpagoside is associated with the NF-κB signaling pathway.

Harpagoside is specifically attributed with anti-inflammatory and positive inotropic effects (increasing myocardial contractions).

Phenolic acids from S. nodosa are considered to be antibacterial, antiseptic, and anthelmintic.

Iridoids are a metabolite group characteristic of the Scrophulariaceae botanical family and present anti-inflammatory activity that may be beneficial in the treatment of inflammation.

The apoptotic and anti-inflammatory effects of Scrophularia aqueous extract have been demonstrated in HaCaT cells; the extract induced these effects potentially through affecting the MAPK pathway and inhibition of the NF-κB pathway.

4. Scientific Evidence by Area of Use

4.1 Wound Healing and Skin Conditions

In Vitro and Animal Evidence

In 2002, Stevenson et al. evaluated the capacity of acylated iridoid glycosides from S. nodosa to affect the growth of fibroblasts using the neutral red assay. These compounds enhanced the growth of human dermal fibroblasts (HDFs) showing a hormetic concentration relationship. Of particular interest were observations that each compound-induced stimulation showed growth greater than that induced by the control test (10% fetal calf serum).

The wound-healing activity of acylated iridoid glycosides was shown in vitro to stimulate the growth of human dermal fibroblasts.

Results in a preclinical study indicated that ethanolic extract of Scrophularia striata could accelerate wound healing and may be a candidate for treating infected burn wounds because of strong anti-bacterial and healing effects.

Hypertrophic scars are caused by abnormal wound healing, and no standard treatment has been made available for them. Scrophularia striata has been reported to accelerate wound healing and has the potential to prevent hypertrophic scar formation. A rabbit ear model study investigated the anti-scarring effects of S. striata extract.

Human (Clinical) Evidence

The most notable human clinical evidence involves Scrophularia striata rather than S. nodosa directly. A double-blind clinical trial was performed on grade 1 and 2 pressure wounds in 120 patients with cerebral-spinal cord lesions, divided into four groups of 30. Topical treatments were performed twice a day; groups included a Scrophularia striata hydroalcoholic extract (SHE) combined with phenytoin, SHE alone applied twice daily, phenytoin alone (control), and a placebo eucerin arm. The extract was used as a 10% topical formulation applied to pressure ulcers.

A separate randomised clinical trial assessed wound healing in patients using Scrophularia striata solution versus standard stoma care. Results indicated a significant improvement in wound healing for the group treated with Scrophularia striata compared to the control group, with a reduction in symptoms such as skin discolouration and tissue overgrowth. The findings support the use of Scrophularia striata as an effective, non-chemical option for enhancing peristomal wound healing.

Evidence characterization: Preclinical in vitro and animal evidence for wound healing across multiple Scrophularia species is moderately consistent. The human clinical data are limited to small or moderate-sized randomized controlled trials in specialized wound populations (spinal cord injury patients, stoma patients), primarily using S. striata. These findings are preliminary and cannot yet be extrapolated broadly to S. nodosa or other figwort species without additional trials.

4.2 Anti-Inflammatory Effects

Several iridoid and phenylethanoid/phenylpropanoid glycosides detected in Scrophularia species, such as harpagoside and verbascoside, possess anti-inflammatory and anti-nociceptive properties. Harpagoside is an active component of Scrophularia ningpoensis that has demonstrated anti-inflammatory and anti-immune effects.

Hypoxia can lead to microglia activation and inflammatory mediator overproduction, and these inflammatory molecules can amplify the neuroinflammatory process and exacerbate neuronal injury. Harpagoside was shown to decrease IκB-α protein phosphorylation and inhibit p65 translocation, suppressing NF-κB activation and HIF-1α generation; the study concluded that the anti-inflammatory mechanism of harpagoside is associated with the NF-κB signaling pathway, and that harpagoside protects against hypoxia-induced toxicity on microglial cells through the HIF-1α pathway.

Evidence characterization: Anti-inflammatory evidence is primarily preclinical (cell culture and animal models), identifying NF-κB pathway suppression and inflammatory mediator modulation as plausible mechanisms. No robust double-blind human clinical trials evaluating figwort for inflammatory conditions have been identified in the peer-reviewed literature.

4.3 Cardiovascular Effects

S. nodosa has traditionally been noted to possess cardiac stimulant properties. A preclinical study investigated potential resistance to ischemia-reperfusion (I/R) injuries following administration of methanolic extract of Scrophularia frigida in isolated rat heart. Male Wistar rat hearts (n = 8–10) were isolated, allowed to equilibrate, and then subjected to 30 minutes of regional ischemia followed by 120 minutes of reperfusion. Administration of the extract improved the flow rate, developed pressure, and maximum and minimum left ventricular dp/dt.

Among the plant's constituents, agents with antioxidant activity play a primary role in preventing and treating ischemic heart injuries, especially arrhythmias; and glycosides can improve cardiac contractility and cell feeding in both ischemic and reperfused conditions.

Evidence characterization: Cardiovascular evidence is entirely preclinical (isolated heart preparations, animal models). No human clinical trials of figwort for cardiac indications have been identified. The presence of cardioactive glycosides raises both potential and safety concerns that have not been addressed in rigorous clinical research.

4.4 Antimicrobial Activity

Biological screening of S. nodosa crude extract and its fractions (hexane, chloroform, ethyl-acetate, n-butanol, and aqueous) on phytotoxicity, cytotoxicity, antibacterial, antifungal, and analgesic activities demonstrated that the fractions exhibited significant antibacterial and antifungal effects.

In laboratory experiments, Scrophularia striata has shown properties to be anti-inflammatory, antibacterial, and antioxidant. Species across the genus have been found to have numerous biological activities including antibacterial and antiprotozoal properties, among others.

Evidence characterization: Antimicrobial activity evidence is confined to in vitro laboratory assays and one clinical context (wound infection in the pressure ulcer trial). No clinical trials isolating antimicrobial efficacy of figwort as a standalone treatment have been published.

4.5 Analgesic Activity

In a preclinical writhing test in mice, analgesic activity results of S. nodosa were found to be highly significant in the crude extract compared to fractions. The crude extract at 500 mg/kg showed 65.6% highest inhibitory response.

Evidence characterization: Analgesic evidence is preclinical only (animal writhing test model). No human clinical data are available for this indication.

4.6 Antitumor and Cytotoxic Activity

Based on numerous animal studies and long-term clinical experience in China, investigators studied the molecular and cellular mechanism underlying the bioactivity of aqueous extract of Scrophularia and its isolated compounds. Seven isolated compounds, unlike the full Scrophularia extract, failed to induce cytotoxicity on HaCaT cells alone, but their combination improved the effect of the extract. Notably, neither iridoids nor phenylpropanoids (harpagide, harpagoside, aucubin, catapol, acetoside, and angoroside C) individually inhibited cell proliferation in these assays.

While S. nodosa exhibits antioxidant properties in vitro, no credible clinical evidence supports anti-cancer claims.

Evidence characterization: In vitro cytotoxic and apoptotic effects have been reported using whole extracts, though individual isolated compounds showed inconsistent results. Evidence for antitumor activity is purely preclinical and cannot be interpreted as clinical evidence of efficacy.

4.7 Neuroprotective Activity

Experimental studies have indicated that Radix Scrophulariae possesses various biological activities, including hepatoprotective activity, anti-inflammatory, neuroprotective, and antipyretic effects. The compounds isolated from S. ningpoensis possess diverse pharmacological properties affecting the cardiovascular, hepatic, and nervous systems, protecting the body against inflammation, oxidation, and carcinogenesis.

Harpagoside has been shown in animal studies to increase body weight and reduce spontaneous activity in Yin-deficiency mice induced by thyroxine. Harpagoside also promoted the proliferation of T lymphocytes and increased the production of IL-2 in spleen lymphocytes, and decreased the contents of cAMP, cGMP, and the value of cAMP/cGMP.

Evidence characterization: Neuroprotective evidence is preclinical, derived from cell culture and murine models. No human neurological trials have been identified.

4.8 Anti-Diabetic and Hepatoprotective Activity

Modern pharmacological studies have confirmed that S. ningpoensis is a valuable Chinese medicinal herb with many pharmacological uses in the treatment of cardiovascular, diabetic, and liver diseases. Among the components of S. ningpoensis, phenylpropanoid glycosides and iridoid glycosides possess anti-inflammatory effects. The plant has been used to treat liver disease, cardiovascular disease, and diabetes, and has antioxidant, anti-inflammatory, and anticarcinogenic effects.

Evidence characterization: Evidence for anti-diabetic and hepatoprotective activity comes primarily from in vitro enzyme inhibition studies (alpha-glucosidase inhibitory activity) and animal models. Clinical human evidence for these indications is not established.

Overall Evidence Assessment

There is limited clinical trial data specifically on figwort. Most of the evidence supporting its use is based on traditional herbal practices and animal studies. Some trials have suggested potential efficacy in treating inflammatory skin conditions and wound healing, but more rigorous clinical studies are needed to confirm these effects.

5. Body Systems and Health Areas Associated with Figwort

The body systems and health areas associated with figwort across traditional and scientific literature include:

• Integumentary system (skin): Traditional use for eczema, psoriasis, pruritus, and wound healing.
• Lymphatic system: Associated with lymphatic conditions, swellings, and swollen lymph nodes.
• Cardiovascular system: Documented as a cardiac stimulant in traditional use.
• Musculoskeletal system: Promoted as potentially beneficial in rheumatism and gout through metabolic detoxification.
• Gastrointestinal system: Characterized in traditional medicine as mildly purgative.
• Renal/urinary system: Used as a "water pill" to relieve bloating by increasing urine production.
• Nervous system: Preclinical evidence suggests neuroprotective and anti-inflammatory effects on neural tissue.

6. Dosage Forms and Reported Dosages

Dosages reported in herbal practice references for Scrophularia nodosa include the following forms and amounts:

• Infusion (tea): 1 tablespoon of herb, infused for 15 minutes, taken three times daily.
• Tincture: 2–4 ml three times daily (1:5 in 45% alcohol), with a reported weekly maximum of 20 ml.
• Dried herb: 2–8 g three times daily.
• Capsules: 250 mg per capsule, 2 capsules three times daily.
• Topical formulation (S. striata, clinical trial): A 10% topical formulation of Scrophularia striata hydroalcoholic extract applied to pressure ulcers, with treatments administered once or twice daily in different trial arms.

Note: These dosages are drawn from herbal reference sources and one clinical trial protocol. They are not equivalent to clinically validated therapeutic dosages confirmed through rigorous human trials, which do not yet exist for this herb.

7. Safety Considerations and Interactions

General Toxicity

Figwort is considered generally safe when used appropriately, but high doses or prolonged use can cause adverse effects such as nausea, diarrhea, or skin irritation. High doses of S. nodosa can be poisonous.

Cardiac Safety

The most clinically significant safety consideration involves the plant's cardioactive constituents. S. nodosa contains cardioactive glycosides and has cardiac stimulant properties. Figwort is specifically contraindicated in ventricular tachycardia. Caution is advised with pre-existing heart conditions and tachycardia.

Pregnancy and Lactation

Figwort is best avoided in pregnancy and lactation. Caution is advised for pregnant or breastfeeding women.

Drug Interactions

Caution is warranted when figwort is combined with cardiac glycoside medications (such as digoxin), given the plant's own cardioactive glycoside content. The plant's saponins might interfere with certain medications, particularly those that affect the liver or digestive system. Persons with ventricular tachycardia should not use figwort; a moderate interaction has been noted with lithium and the combination should be approached cautiously with a health provider.

Species Specificity

Scrophularia nodosa has a distinct phytochemical profile compared to S. auriculata or S. marilandica. Species are not interchangeable in terms of potency or constituent profile, and product labels should specify botanical names.

Summary of Contraindications

• Ventricular tachycardia (absolute contraindication).
• Pregnancy, lactation, and pre-existing heart conditions (use with caution or avoid).
• Concurrent use with cardiac glycoside drugs (additive cardiac effects possible).
• Concurrent lithium therapy (moderate interaction concern).

References

• Pasdaran A, Hamedi A. "The genus Scrophularia: a source of iridoids and terpenoids with a diverse biological activity." Pharmaceutical Biology. 2017. PMC6130519.
• Pasdaran A, Hamedi A. "The genus Scrophularia: a source of iridoids and terpenoids with a diverse biological activity." PubMed PMID 29125010.
• Pharmacology, phytochemistry, and traditional uses of Scrophularia ningpoensis Hemsl. PubMed PMID 33338592.
• Scrophularia ningpoensis Hemsl: a review of its phytochemistry, pharmacology, quality control and pharmacokinetics. Journal of Pharmacy and Pharmacology. 2021.
• Ahmad M et al. "Spasmolytic effects of Scrophularia nodosa extract on isolated rabbit intestine." PubMed PMID 22186340.
• Phytochemical Analysis and In-vitro Bioactivity of Scrophularia umbrosa Rhizome. PMC5985186.
• Radix Scrophulariae extracts (harpagoside) suppress hypoxia-induced microglial activation and neurotoxicity. PMC4570756.
• Cardioprotective Effects of Methanolic Extract of Scrophularia frigida on Ischemia-Reperfusion-Induced Injuries in Isolated Rat Heart. PMC5963644.
• Effects of Scrophularia ningpoensis Hemsl. on Inhibition of Proliferation, Apoptosis Induction and NF-κB Signaling of Immortalized and Cancer Cell Lines. PMC3763631.
• Iridoid and phenylethanoid/phenylpropanoid metabolite profiles of Scrophularia and Verbascum species used medicinally in North America. PMC7402375.
• Changes in the Harpagide, Harpagoside, and Verbascoside Content of Field-Grown Scrophularia lanceolata and Scrophularia marilandica. PMC8308087.
• Bagheri Z et al. "The Antimicrobial and Healing Effect of Scrophularia striata Boiss Hydroalcoholic Extract on First- and Second-Grade Pressure Wounds in Patients with Brain and Spinal Cord Injury: A Randomized Clinical Trial." PMC9722278. 2022.
• Assessment of the Effect of Topical Scrophularia Striata Solution on Healing of Peristomal Wound. PMC12011406.
• Hydroalcoholic Extract of Scrophularia Striata Attenuates Hypertrophic Scar, Suppresses Collagen Synthesis, and Stimulates MMP2 and 9 Gene Expression in Rabbit Ear Model. PMC9510145.
• Kampo herbal ointments for skin wound healing. Frontiers in Pharmacology. 2023.
• The Healing Effect of Scrophularia Striata on Experimental Burn Wounds Infected to Pseudomonas Aeruginosa in Rat. PMC4298860.
• Scrophularia — an overview. ScienceDirect Topics.
• Pharmacology, phytochemistry, and traditional uses of Scrophularia ningpoensis Hemsl. Journal of Ethnopharmacology. 2020.
• Figwort Ingredient Monograph. WebMD/Natural Medicines.
• Figwort: Health Benefits, Side Effects, Uses, Dose & Precautions. RxList.
• Scrophularia nodosa. The Naturopathic Herbalist (Dr. Marisa Marciano, ND).
• Scrophularia nodosa L., Common Figwort. Botanical Society of Britain & Ireland (BSBI).
• Ahmad M et al. Biological screening of Scrophularia nodosa extract and its fractions. Academia.edu.